Duncan Williams Asset Management LLC Purchases 20,450 Shares of Prothena Co. plc (NASDAQ:PRTA)

Duncan Williams Asset Management LLC lifted its position in shares of Prothena Co. plc (NASDAQ:PRTA) by 41.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 69,199 shares of the biotechnology company’s stock after buying an additional 20,450 shares during the quarter. Duncan Williams Asset Management LLC owned approximately 0.13% of Prothena worth $958,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Orion Portfolio Solutions LLC lifted its stake in shares of Prothena by 4.4% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 17,531 shares of the biotechnology company’s stock worth $293,000 after purchasing an additional 739 shares during the last quarter. Pinnacle Associates Ltd. lifted its position in shares of Prothena by 2.3% during the third quarter. Pinnacle Associates Ltd. now owns 125,747 shares of the biotechnology company’s stock valued at $2,104,000 after buying an additional 2,847 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Prothena by 3.8% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 86,071 shares of the biotechnology company’s stock valued at $1,440,000 after buying an additional 3,163 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Prothena by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,344 shares of the biotechnology company’s stock worth $173,000 after buying an additional 4,026 shares during the last quarter. Finally, Ensign Peak Advisors Inc raised its stake in shares of Prothena by 30.4% during the 2nd quarter. Ensign Peak Advisors Inc now owns 21,643 shares of the biotechnology company’s stock worth $447,000 after acquiring an additional 5,050 shares in the last quarter. Hedge funds and other institutional investors own 97.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on PRTA shares. StockNews.com downgraded shares of Prothena from a “hold” rating to a “sell” rating in a research note on Tuesday, November 19th. HC Wainwright reaffirmed a “buy” rating and set a $48.00 target price (down from $84.00) on shares of Prothena in a research report on Friday, December 20th. Cantor Fitzgerald reissued an “overweight” rating on shares of Prothena in a report on Monday, September 30th. Chardan Capital started coverage on shares of Prothena in a report on Friday, December 20th. They set a “buy” rating and a $40.00 price objective on the stock. Finally, Bank of America decreased their price objective on shares of Prothena from $26.00 to $22.00 and set a “neutral” rating for the company in a research report on Thursday, December 19th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $46.50.

Prothena Trading Up 0.9 %

Shares of NASDAQ:PRTA opened at $15.62 on Friday. Prothena Co. plc has a twelve month low of $11.70 and a twelve month high of $33.84. The company’s 50 day moving average is $14.31 and its 200 day moving average is $17.95.

Prothena (NASDAQ:PRTA) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.18) by $0.08. Prothena had a negative return on equity of 24.19% and a negative net margin of 98.86%. The firm had revenue of $0.97 million for the quarter, compared to analyst estimates of $1.22 million. During the same period last year, the company earned $0.38 earnings per share. Prothena’s revenue for the quarter was down 98.9% compared to the same quarter last year. As a group, research analysts expect that Prothena Co. plc will post -2.24 earnings per share for the current fiscal year.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.